share_log

金城医药(300233.SZ)：药监局批准东方略与美国 Inovio Pharmaceuticals共同研发的全球首款HPV治疗性疫苗VGX-3100针对 HPV-16/18相关肛门癌前病变的II期临床试验申请

Shandong Jincheng Pharmaceutical Group (300233.SZ): The FDA has approved the Phase II clinical trial application for the world's first HPV therapeutic vaccine VGX-3100 jointly developed by Dongfanglue and USA Inovio Pharmaceuticals, targeting HPV-16/18-re

Gelonghui Finance ·  Sep 23 08:41

Jincheng Pharmaceutical (300233.SZ) announced on September 23 that on September 20, 2024, Dongfang Lue received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the Phase II clinical trial application for the global first HPV therapeutic vaccine VGX-3100 jointly developed by Dongfang Lue and Inovio Pharmaceuticals, Inc. of usa targeting HPV-16/18-related anal precancerous lesions. The approval of the Phase II clinical trial application for HPV-16/18-related anal precancerous lesions marks another important progress for VGX-3100 after the clinical trial indication of precancerous cervical lesions has been approved.

It is reported that Beijing Dongfang Lve Biomedical Technology Co., Ltd. (referred to as "Dongfang Lue") is a joint venture company of Shanghai Qian De Equity Investment Partnership Enterprise (Limited Partnership), in which Shandong Jincheng Medical Group Co., Ltd. has invested in the shanghai private equity.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment